Markets

Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis

Jul 22, 2026 · 07:32 AM ET· updated 1h ago

Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal

Why It Matters

Zoetis just started selling a new medicine called Portela in Canada and Europe that helps animals with joint pain feel better longer. When a company launches a new product successfully, it can mean more customers and sales ahead, so that's something to watch.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ZTS75.39

+0.04 (+0.05%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.